Pharmacoeconomic evaluation of Secukinumab use as a first- line biologic in patients with psoriatic arthritis

作者
Roza Ismailovna Yagudina,A.Yu. Kulikov,V.G. Serpik,P.A. Logvinyuk,M.V. Protsenko,N. G. Goloenko,T.V. Korotaeva,E.V. Zhilyaev,L.P. Evstigneeva,K.A. Lytkina
出处
期刊:Фармакоэкономика. Теория и практика [Moscow Pharmaceutical Society]
卷期号:6 (4): 20-28 被引量:2
标识
DOI:10.30809/phe.4.2018.3
摘要

Possessing a high prevalence and disability, psoriatic arthritis (PsA) is a serious socio-economic burden for the patient and for society. Therefore, the choice of the PsA treatment strategy requires focusing on not only the prevention and control of the disease but also the effective allocation of the available resources of the healthcare system. Objective. In this regard, the purpose of this study was to conduct a comparative pharmacoeconomic evaluation of biologics: secukinumab (Cosentyx), golimumab (Simponi®), certolizumab pegol (Cimzia®), Ustekinumab (Stelara®), adalimumab (Humira®), etanercept (Enbrel®) and infliximab (Remicade®, Flammegis®, Infliximab produced by local BIOCAD company). Materials and methods. Based on data on the effectiveness of compared treatment regimens, data on the cost of drugs and medical services, as well as the frequency of their provision, an analysis of direct costs, cost-effectiveness analysis, as well as budget impact analysis were carried out. Results. The cost analysis educed that the amount of direct costs for treatment with secukinumab 150 mg for ‘biologic-naive’ patients with active PsA is on average 28% and 40% lower than the cost of treatment with certolizumab pegol, golimumab, ustekinumab, adalimumab, etanercept and infliximab in the first and subsequent years of therapy, in accordance. Estimation of costs and efficacy showed that treatment of PsA with secukinumab 150 mg is characterized by lower costs per unit of effectiveness (ACR 20/50/70 response), relative to the indicators of the compared drugs in the first and subsequent years of therapy. The assumed prescription of secukinumab instead of certolizumab pegol, golimumab, ustekinumab, adalimumab, etanercept, and infliximab (including biosimilar) 19% of patients with active PsA leads to budget savings of 468 million rubles and 1.5 billion rubles for the first and three years of treatment, in accordance, on the calculated patient population. Conclusion. According to the results of the study, the pharmacoeconomic feasibility of using secukinumab 150 mg as a first-line line biologic for the treatment of active PsA has been established.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
王一硕发布了新的文献求助10
刚刚
今后的应助被亦天凛采纳,获得10
刚刚
cdercder的应助被胡萝卜卜采纳,获得10
刚刚
花薇Liv完成签到,获得积分10
2秒前
积极的中蓝完成签到,获得积分10
2秒前
独特乘云发布了新的文献求助10
4秒前
4秒前
Young完成签到,获得积分20
4秒前
5秒前
激昂的海豚完成签到,获得积分10
5秒前
6秒前
152455完成签到 ,获得积分10
6秒前
6秒前
April发布了新的文献求助10
9秒前
22发布了新的文献求助10
9秒前
9秒前
丘比特的应助被栗子味汽水采纳,获得10
10秒前
xmhxpz完成签到,获得积分10
10秒前
聪慧含芙发布了新的文献求助10
11秒前
wang1完成签到,获得积分10
11秒前
2580852qwe完成签到 ,获得积分10
13秒前
经济管理学渣完成签到,获得积分10
14秒前
lucky发布了新的文献求助10
15秒前
11JIN完成签到 ,获得积分10
15秒前
李健的应助被白华苍松采纳,获得10
15秒前
16秒前
wang1发布了新的文献求助10
16秒前
万能图书馆的应助被YAM采纳,获得10
16秒前
机灵凝阳完成签到 ,获得积分10
16秒前
zzzlan完成签到,获得积分20
17秒前
初景的应助被吕小菜采纳,获得20
17秒前
molihuakai的应助被六六采纳,获得10
18秒前
搜集达人的应助被22采纳,获得10
18秒前
吧KO完成签到,获得积分10
18秒前
peike完成签到,获得积分10
19秒前
香芋宝完成签到,获得积分10
20秒前
20秒前
咖喱完成签到,获得积分10
21秒前
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193438
求助须知:如何正确求助?哪些是违规求助? 9579666
关于积分的说明 21866723
捐赠科研通 7793099
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560719
邀请新用户注册赠送积分活动 2484156